679101

Vitamin D₃, 1α, 25-Dihydroxy-

CAS 32222-06-3 prevents the development of clinical diabetes in NOD mice, an animal model of human autoimmune diabetes.

• Synonym(s): Vitamin D₃, 1α, 25-Dihydroxy-, 1,25-(OH)₂-D₃, Calcitriol
• Empirical Formula (Hill Notation): C₂₇H₄₄O₃
• CAS Number: 32222-06-3
• Molecular Weight: 416.64
• UNSPSC Code: 12352205
• NACRES: NA.21
• MDL number: MFCD00867079

Properties

• Quality Segment: 100
• description: Merck USA index - 14, 1644
• assay: ≥95% (HPLC)
• form: solid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze, protect from light
• solubility: DMSO: 50 mg/mL, ethanol: soluble
• shipped in: wet ice
• storage temp.: −70°C
• SMILES string: O[C@H]1C[C@@H](C(=C)\C(=C/C=C2/[C@H]3[C@@]([C@H](CC3)[C@@H](CCCC(O)(C)C)C)(CCC/2)C)\C1)O
• InChI: 1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1
• InChI key: GMRQFYUYWCNGIN-NKMMMXOESA-N

Description

General description

Active hormonal form of vitamin D, formed by the renal 1-hydroxylation of 25-(OH)D₃. Has immunomodulatory properties in vitro and in vivo. Prevents the development of clinical diabetes in NOD mice, which are an animal model of human autoimmune diabetes. Induces reversible hydrolysis of the sphingomyelin cycle and generates ceramide. Stimulates intestinal Ca²⁺ and phosphate transport and mobilizes Ca²⁺ from bone. Involved in cellular differentiation, carcinogenesis, and insulin secretion.

Has immunomodulatory properties in vitro and in vivo. Prevents the development of clinical diabetes in NOD mice, an animal model of human autoimmune diabetes. Regulates c-myc transcription. Induces reversible hydrolysis of sphingomyelin cycle and generates ceramide. Stimulates intestinal Ca²⁺ and phosphate transport and mobilizes Ca²⁺ from bone. Also available as a 1 mM solution in DMSO (Cat. No. 509721).

Application

• Vitamin D deficiency or resistance and hypophosphatemia.: Discusses the complex interplay between vitamin D metabolism and phosphate homeostasis, emphasizing the crucial role of 1α,25-Dihydroxy-vitamin D3 in managing and understanding bone mineral disorders and their systemic implications (Sarathi et al., 2024).


• Altered Expression of Vitamin D Metabolism Genes and Circulating MicroRNAs in PBMCs of Patients with Type 1 Diabetes.: Investigates how 1α,25-Dihydroxy-vitamin D3 influences gene expression and microRNA profiles in peripheral blood mononuclear cells, linking vitamin D status with autoimmune processes in diabetes (Al-Nakhle et al., 2023).


• 1α,25-Dihydroxyvitamin D(3) Improves Follicular Development and Steroid Hormone Biosynthesis by Regulating Vitamin D Receptor in the Layers Model.: Demonstrates the role of 1α,25-Dihydroxy-vitamin D3 in enhancing reproductive functions and hormonal balance through its action on the vitamin D receptor, providing insights into fertility management (Cheng et al., 2023).


• 1α,25(OH)(2)D(3) Promotes the Autophagy of Porcine Ovarian Granulosa Cells as a Protective Mechanism against ROS through the BNIP3/PINK1 Pathway.: This study presents the protective effects of 1α,25-Dihydroxy-vitamin D3 on ovarian cells under oxidative stress, suggesting mechanisms that could be exploited for therapeutic interventions in reproductive health (Wang et al., 2023).

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-70°C). Stock solutions are stable for up to 3 months at -70°C.

Other Notes

Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.

Semizarov, D., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 15412.
Hannun, Y.A. 1994. J. Biol. Chem.269, 3125.
Mathieu, C., et al. 1994. Diabetologica37, 552.
Thomasset, M. 1994. Pathol. Biol. 42, 163.
Horton, W.E., Jr., et al. 1991. J. Biol. Chem.266, 24804.
Larsen, C.G., et al. 1991. Biochem. Biophys. Res. Commun.176, 1020.
Thavarajah, M., et al. 1991. Biochem. Biophys. Res. Commun.176, 1189.
Wakasugi, M., et al. 1991. Prostaglandins42, 127.
Matsumoto, K., et al. 1990. Biochem. Biophys. Res. Commun.166, 916.
Simpson, R.U., et al. 1989. J. Biol. Chem.264, 19710.
DeLuca, H.F., and Schnoes, H.K. 1983. Annu. Rev. Biochem.52, 411.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Highly Toxic & Carcinogenic / Teratogenic (I)

Safety Information

• pictograms: GHS06,GHS08
• signalword: Danger
• hcodes: H300 + H310 + H330,H372
• pcodes: P260 - P262 - P280 - P302 + P352 + P310 - P304 + P340 + P310 - P314
• Hazard Classifications: Acute Tox. 1 Oral - Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - STOT RE 1
• Storage Class: 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
• wgk: WGK 2
• flash_point_f: Not applicable
• flash_point_c: Not applicable